Medical University of Vienna - Medizinische Universität Wien
Welcome,         Profile    Billing    Logout  
 3 Trials 
2 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vossen, Matthias G
REPAVID-22, NCT05254990 / 2021-006951-32: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Recruiting
3
526
Europe, US, RoW
Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo
Dompé Farmaceutici S.p.A
Infectious Pneumonia, Severe COVID-19
09/24
10/24
FORTRESS, NCT02979951: Fosfomycin i.v. for Treatment of Severely Infected Patients

Recruiting
N/A
1000
Europe
Infectopharm Arzneimittel GmbH, INPADS GmbH, Dr. Oestreich + Partner GmbH
Bacterial Infections, Bone Diseases, Infectious, Osteomyelitis, Central Nervous System Bacterial Infections, Meningitis, Bacterial, Encephalitis, Brain Abscess, Urinary Tract Infections, Respiratory Tract Infections, Pneumonia, Bacterial, Skin Diseases, Bacterial, Soft Tissue Infections, Intraabdominal Infections, Sepsis, Bacteremia, Endocarditis, Bacterial
 
 

Download Options